All News
ACR Best Abstracts - Day 2
Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.
Here are the RheumNow faculty selections for #ACRbest abstracts today:
#ACR22 Abstr#1764 In addition to race, what social health aspect to consider when assessing #lupus epidemiology? A study identified urbanicity and area deprivation index were associated with SLE diagnosis. Could those living in the city = better access and diagnosis? @RheumNow https://t.co/PsNt8vQufs
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Urine Proteomics in SLE with Dr. Michelle Petri
Dr. Michelle Petri discusses abstract 0536, Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria, being presented Saturday at #ACR22.
https://t.co/rBDnbSqQCI https://t.co/WfERf1k5VB
Links:
Dr. John Cush RheumNow ( View Tweet)
PC4d≥10 MFI is associated with thrombosis in SLE and predicts future arterial thrombosis. Abs 1442 #ACR22 @RheumNow https://t.co/zg7rrOSALs https://t.co/Hs2eOa2vxJ
Dr. Rachel Tate uptoTate ( View Tweet)
Numerically, SLE was more common in cITP patients. Risks include +ANA and female sex. Abs 1461 #ACR22 @RheumNow https://t.co/0kyqlVphac https://t.co/HfYKCMybdL
Dr. Rachel Tate uptoTate ( View Tweet)
While myositis in the setting of SLE was found to be around 5% in Abs 1453, it was not associated with mortality. #ACR22 @RheumNow https://t.co/hLLuYoXsCv https://t.co/44XGhbPxzW
Dr. Rachel Tate uptoTate ( View Tweet)
Abst0327 #ACR22 SMART-SLE Monitoring
Some SLE patients with +dsDNA have persistent positivity, others have fluctuations
Anti-dsDNA in persistently positive HR 1.56 for flare risk
Change (up or down!) in dsDNA more than 2x prior visit for fluctuating patients: HR 1.43
@RheumNow https://t.co/YwDPTYWPLu
Eric Dein ericdeinmd ( View Tweet)
Abst0326 #ACR22 Anti-Mitochondrial Ab in SLE
Whole mitochondrial (AwMA), AmtDNA or AmtRNA - higher in SLE compared to controls
AwMA predictive of death, AmtDNA and AmtRNA predictive of nephritis
@Rheumnow https://t.co/d98HSHnJVE
Eric Dein ericdeinmd ( View Tweet)
Abst0328 #ACR22. Predicting UCTD to CTD Meta-Analysis
Factors for SLE transition: younger age, serositis, dsDNA
SSc transition: puffy finger, NFC, or SSc antibodies
No studies wo moderate or high risk of bias
Limited studies on biomarkers for SLE, need more studies
@Rheumnow https://t.co/GofGF8TkCx
Eric Dein ericdeinmd ( View Tweet)
Is channelling bias a risk, because of treating clinicians 'protecting' pre-existing autoimmune dx pts: maybe?
Certainly in practice, these pts might get less combo immunoRx; this @mcgillu data would suggest so
Much more to understand across tumor streams
ABST0760 #ACR22 https://t.co/z1rhAJZ9gj
David Liew drdavidliew ( View Tweet)
Only 4 minutes to discuss adherence in #SLE. Implementation of discussion if <80% of meds filled. Academic docs - 20/24 used + reinforcement, validated in 17 Pts, 11/24 asked open ended ?s. Pts thought it was right timing. ?does it change behaviour- ? Abst0063 @RheumNow #ACR22 https://t.co/UQbRgw5Emj
Janet Pope Janetbirdope ( View Tweet)
Pike et al. Deucravactinib (TYK2i) in SLE. + on SRI(4) week 32. + SRI(4),BICLA, LLDAS, CLASI-50, swollen and tender joint counts week 48. Strange, the lowest dose (3mg bd) seems best. @RheumNow #ACR22 Abstr#1117 #ACRbest https://t.co/o4902tvZs8 https://t.co/t8oeMRGUS7
Richard Conway RichardPAConway ( View Tweet)
2000 IU/day vitamin D led to significantly reduced incidence of autoimmune diseases in Abs 1200 over 5.3 years, but after trial termination, protective effects dissipated and were no longer significant. #ACR22 @RheumNow https://t.co/sLwoxeCR3y https://t.co/47wpWXF1W7
Dr. Rachel Tate uptoTate ( View Tweet)
13S150. Draft ACR/EULAR APLS Classif Crit #ACR22
Entry: Clinical & +aPL w/in 3 yr
Then: Additive crit
-Don't count other cause
Clinical Domains: Macrovasc VTE, Macrovasc AT, Microvasc, Obst, Cardiac, Hematology
Lab: +LA, aCL/B2GP IgM/IgG/titer
Total: 3+ clin, 3+ lab
@RheumNow https://t.co/YeKW0orjZC
Eric Dein ericdeinmd ( View Tweet)
Plenary:
Tyrosine kinase 2 (TYK2)
◦ Mediates signaling of Type I IFNs, IL-23, and IL-12
◦ Key cytokines involved in lupus pathogenesis
◦ Deucravacitinib oral TYK2 inhibitor
◦ Phase 2 RCT in SLE showed efficacy
Pike M Abs1117 https://t.co/eJhNsM02Vl #ACR22 @RheumNow https://t.co/C6JQqR1DLj
Dr. Antoni Chan synovialjoints ( View Tweet)
Carter et al. Case series showing rapid effect of anifrolumab in refractory discoid lupus and SCLE. @RheumNow #ACR22 Abstr#0974 https://t.co/RjnNxjGJoP…
Richard Conway RichardPAConway ( View Tweet)
Are preexisting autoimmune dx pts okay for
PD-1i/CTLA-4i combo immunoRx
(vs PD-1i single agent)?
Common question in practice for your rheum pts who get cancer
Combo ICI means:
de novo irAE: double risk
flares: same risk
Give our pts what they need!
ABST0757 #ACR22 @RheumNow https://t.co/Vs1AoM54Ut
David Liew drdavidliew ( View Tweet)
Zheng et al. Celiac disease more common in SLE aOR 2.88 (95%CI 2.60 –3.31). More common in white females. Assoc higher hospitalization cost and increased LOS @RheumNow #ACR22 Abstr#1192 https://t.co/kdwLmpIxNN https://t.co/ZdQJQn3QIF
Richard Conway RichardPAConway ( View Tweet)
Phase 2 efficacy and safety of deucravaticinib (TYK2i) in mod-severe SLE. Met primary endpoint (SRI4) for 3mg and 6mg doses (but not 12mg). No signal for HZ but increased oral herpes. Bigger numbers will be helpful.
@RheumNow #ACR22 #plenary #ACRBest https://t.co/SjW1OSQzdM
Julian Segan JulianSegan ( View Tweet)
DEUC showed statistically significant and sustained clinical efficacy in SRI(4) responses versus PBO and was well tolerated in SLE. Plenary Abs 1117 #ACR22 @RheumNow https://t.co/iHPiA8FCwO https://t.co/A0FQ7zwL64
Dr. Rachel Tate uptoTate ( View Tweet)
